Patents Assigned to CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY
-
Patent number: 11944969Abstract: Systems and methods are provided to assist in developing a precision medicine approach using a microfluidic cell having a releasable, aqueous interfacial film to separate tissue channels. The approach can include a personalized medicine treatment plan. The systems and methods emulate cellular communication in a disease state in a more accurate aqueous environment and provide data on the interaction between the cells that can be used to develop a treatment for a subject in need. The systems and methods also can be used to assess the effect of a particular treatment, such as a drug therapy, radiation therapy, or a combination thereof, for example. The systems and methods can show how a particular therapy is affected by any of several known factors including, but not limited to, the sex of the subject, the age of the subject, hereditary factors or other genetic predispositions, as well as perhaps other physiological states of the subject, or a combination thereof.Type: GrantFiled: July 14, 2022Date of Patent: April 2, 2024Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventor: Fakhrul Ahsan
-
Patent number: 11318184Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: June 12, 2020Date of Patent: May 3, 2022Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventor: Xiaodong Feng
-
Patent number: 10973877Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).Type: GrantFiled: August 18, 2020Date of Patent: April 13, 2021Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACYInventor: Xiaodong Feng
-
Patent number: 10973778Abstract: Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.Type: GrantFiled: January 31, 2019Date of Patent: April 13, 2021Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventors: Indiran Pather, Tibebe Zewdie Woldemariam
-
Patent number: 10786548Abstract: The teachings generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).Type: GrantFiled: August 20, 2019Date of Patent: September 29, 2020Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACYInventor: Xiadong Feng
-
Patent number: 10722555Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: December 18, 2014Date of Patent: July 28, 2020Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventor: Xiaodong Feng
-
Patent number: 10231940Abstract: Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.Type: GrantFiled: December 17, 2012Date of Patent: March 19, 2019Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventors: Indiran Pather, Tibebe Zewdie Woldemariam
-
Patent number: 8946159Abstract: A combination therapy is provided and is directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. The compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: December 22, 2011Date of Patent: February 3, 2015Assignee: California Northstate College of Pharmacy, LLCInventor: Xiaodong Feng
-
Patent number: 8815805Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: November 7, 2012Date of Patent: August 26, 2014Assignee: California Northstate College of Pharmacy, LLCInventor: Xiaodong Feng
-
Patent number: 8815220Abstract: Sunscreen compositions containing an extract of Curcuma longa L. are provided, the sunscreens having an absorption that spans the UVA and UVB ranges in a manner that meets updated FDA recommendations without requiring the addition of titanium dioxide. The sunscreens can also include an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. Microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts in the sunscreens.Type: GrantFiled: December 17, 2012Date of Patent: August 26, 2014Assignee: California Northstate College of Pharmacy, LLCInventors: Indiran Pather, Tibebe Zewdie Woldemariam
-
Publication number: 20140056830Abstract: Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.Type: ApplicationFiled: December 17, 2012Publication date: February 27, 2014Applicant: California Northstate College of Pharmacy, LLCInventors: Indiran Pather, Tibebe Zewdie Woldemariam
-
Publication number: 20140056829Abstract: Sunscreen compositions containing an extract of Curcuma longa L. are provided, the sunscreens having an absorption that spans the UVA and UVB ranges in a manner that meets updated FDA recommendations without requiring the addition of titanium dioxide. The sunscreens can also include an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. Microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts in the sunscreens.Type: ApplicationFiled: December 17, 2012Publication date: February 27, 2014Applicant: California Northstate College of Pharmacy, LLCInventors: Indiran Pather, Tibebe Zewdie Woldemariam
-
Publication number: 20130225495Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: ApplicationFiled: November 7, 2012Publication date: August 29, 2013Applicant: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACYInventor: CALIFORNIA NORTHSTATE COLLEGE OF PHAR
-
Publication number: 20130225494Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?V?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).Type: ApplicationFiled: November 7, 2012Publication date: August 29, 2013Applicant: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACYInventor: CALIFORNIA NORTHSTATE COLLEGE OF PHAR